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Polyunsaturated fatty acids (PUFAs) have been proposed to play a role in the risk of various 
cancers. For cutaneous melanoma, observational epidemiological studies suggest an 
association with PUFAs but the evidence is inadequate. Hence, we conducted the first ever 
Mendelian randomisation study to assess if PUFA levels are causally related to melanoma 
risk. Our results suggest that the effect of PUFA levels on melanoma risk is either zero or 
very small. 
Abstract  
Melanoma is the deadliest form of skin cancer, mainly affecting populations of European 
ancestry. Some observational studies suggest that particular diets reduce melanoma risk - 
putatively through an increase in polyunsaturated fatty acid (PUFA) consumption. However, 
interpretation of these observational findings is difficult due to residual confounding or 
reverse causality. To date, a randomised controlled trial has not been carried out to examine 
the relationship between PUFAs and melanoma. Hence, we performed a Mendelian 
randomisation (MR) study to evaluate the link between PUFAs and melanoma.  
To perform MR we used summary results from the largest risk genome-wide association 
study (GWAS) meta-analysis of melanoma, consisting of 12,874 cases and 23,203 controls. 
As instrumental variables we selected SNPs associated with PUFA levels from a GWAS meta-
analysis of PUFA levels, from the CHARGE consortium. We used the inverse variance 
weighted method to estimate a causal odds ratio. To aid interpretation, we established a 
HWﾐIｴﾏ;ヴﾆ さﾉ;ヴｪWざ ヮヴWSｷIデWS Iｴ;ﾐｪW ｷﾐ PUFAゲ in which, for example, an increase in 
docosahexaenoic acid (DPA) of 0.17 units (equal to 1 standard deviation) moves a person 
from the 17th percentile to the median. 
Raising PUFA levels by a large amount (increasing DPA by 0.17 units) only negligibly changed 
melanoma risk - Odds Ratio [OR] = 1.03 (95% Confidence Interval [CI] = 0.96 - 1.10). Other 
PUFAs yielded similar results as DPA. Our MR analysis suggests that the effect of PUFA levels 
on melanoma risk is either zero or very small. 




Melanoma, the most aggressive form of skin cancer, has an incidence of approximately 
132,000 cases worldwide each year1. Melanomas arise due to malignant transformation of 
melanocytes, the cells responsible for pigmentation of the skin. Global incidence of melanoma 
is continuously rising, leading to a significant burden on health care systems1. Currently, the 
risk factors for melanoma are incompletely understood. Therefore, it is crucial to discover the 
role of modifiable risk factors on melanomagenesis to strengthen primary prevention 
strategies, allowing early intervention and subsequently reducing mortality, morbidity and 
health care costs. 
The aetiology of melanoma is complex. Fair skin, red hair2, a higher number of atypical 
naevi, a tendency to freckle3, intermittent or increased exposure to ultra-violet radiation 
(UVR)4-6 and a family history of melanoma7 are well known risk factors. Exposure to UVR is 
the principal environmental risk factor for cutaneous melanoma8 and UVR induces the vast 
majority of melanoma-initiating somatic mutations9. One of the biological pathways through 
which UVR is hypothesized to promote melanomagenesis is by immunosuppression8. Recent 
research has shown that dietary modification has potential to mitigate UVR-induced 
immunosuppression10. For example, a recent randomised controlled trial (RCT) has shown 
that n-3 polyunsaturated fatty acid (PUFA) supplementation has a beneficial effect on skin 
immunity and reduces the harmful effects from sun damage11. We therefore hypothesized 
that nutrition may play a role in melanoma risk. 
Identification of nutritional interventions is potentially of high importance as they can easily 
be integrated into primary prevention12. Of particular interest is the Mediterranean diet, 
which includes abundant consumption of legumes, vegetables, fruits, cereals, and olive oil, a 
moderate intake of fish and alcohol (mostly wine), a moderate to low intake of dairy 
products, and a low intake of processed meat13. A traditional Mediterranean diet is 
protective for all-cause mortality14 and many individual diseases, including prostate cancer 
15, colorectal cancer16が Aﾉ┣ｴWｷﾏWヴげゲ SｷゲW;ゲW17, coronary heart disease18, diabetes mellitus19, 
P;ヴﾆｷﾐゲﾗﾐげゲ SｷゲW;ゲW20 . 
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It has been proposed that the protective effect on cancers is related to the optimal balance 
between n-6 and n-3 fatty acids in the Mediterranean diet21, 22 These n-3 and n-6 fatty acids 
reduce tumour growth by inhibiting cell growth, apoptosis, angiogenesis and inflammation 
23, 24. Observational studies have discovered that higher levels of dietary n-3 fatty acid intake 
are inversely associated with melanoma risk25-27. A hospital-based case-control study 
conducted in Italy showed that weekly consumption of fatty fish that was rich in n-3 fatty 
acids was associated with a reduced risk of melanoma (Odds Ratio [OR] = 0.52, 95% 
Confidence interval [CI] = 0.34に0.78). A study performed on a mouse model identified that 
Eicosapentaenoic acid (EPA) (n-3 fatty acid) protected against UVR induced carcinogenesis 
28. In vitro experimental studies have shown that EPA and DHA (n-3 fatty acid) inhibit 
proliferation of cultured human melanoma cells29. Collectively, these results suggest that 
modifying PUFAs may have a role in reducing melanoma incidence.  
Although observational studies make a significant contribution to the field of medical 
research, outcomes from many such studies have failed to validate in randomised controlled 
trials30-33. This lack of concordance is likely due to confounding and/or reverse causation in 
observational studies34. Confounding occurs when an unmeasured risk factor/variable is 
associated with both the measured risk factor and outcome, distorting the true association 
of the measured risk factor and outcome. Reverse causation masks the true effect by 
causally relating the outcome to the risk factor. Although the RCT approach is the gold 
standard for accessing causality, their use is frequently constrained by ethical and practical 
issues of administering some interventions. Further, performing a RCT may be time 
consuming; sometimes it is a challenge to retain the participants until the end of the study 
and bias may be introduced if participants do not adhere to the intervention. 
Mendelian randomisation (MR) is a method in which genetic variants, usually single 
nucleotide polymorphisms (SNPs), are used to test whether a modifiable exposure (risk 
factor) is causally related to an outcome (disease). Furthermore, the magnitude and 
direction of any causal relationship can be determined. MR can be reｪ;ヴSWS ;ゲ ; さﾐ;デ┌ヴ;ﾉざ 
RCT, in that genetic variants are used as instrumental variables for the risk factors in order 
to infer whether the risk factors are causal for the disease35. The random allocation of alleles 
during meiosis is conceptually similar to a RCT design, and is independent of confounding 
from environmental exposures. Reverse causation is avoided by the unidirectional flow from 
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gene to phenotype to disease; the disease cannot alter the gene. MR also has some 
advantages over RCTs in terms of ethical issues, feasibility, time and cost. 
MR makes three key assumptions, and violations of these assumptions will lead to biases. 
Firstly, there should be strong evidence for the association of the genetic instrument with 
the risk factor (strong instrument assumption). Secondly, any confounding variables which 
are associated with risk factor and outcome should not be associated with the genetic 
variant (independence assumption) The third assumption is that the outcome/disease of 
interest is only associated with the genetic instrument through the risk factor/exposure of 
interest which acts as a proxy (exclusion restriction assumption) (Figure 1)34. 
We performed MR to explore the possible causal relationship between genetically predicted 
PUFA exposures and melanoma. In order to draw strong conclusions using MR, power must 
be high; the size of our large melanoma GWAS and the high proportion of variance 
explained by SNPs associated with PUFA suggests our study is highly powered for MR.  We  
calculated the power using mRnd software36. With an OR of 0.52 for the observational study 
result, and using the instrument with the least variance explained (0.65% variance, 
rs2236212 for DHA) the power was 99%. Unusually among complex traits, the few SNPs 
associated with PUFA levels explain a large proportion of the variance in the trait. For 
example, SNP rs174547 explains 8.6% of variance in docosapentaenoic acid (DPA) 37 and 
32.6% of variance in arachidonic acid (AA)38, 39. The different PUFAs share a common 
metabolic pathway (Figure 2) and SNPs known to influence one PUFA typically also have 
strong effects on the others. We examined the causality of melanoma using n-3 fatty acids 
docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), ü-
linolenic acid (ALA) and n-6 fatty acids linoleic acid (LA) and arachidonic acid (AA). 
Methods  
Study population 
We used summary data from the largest melanoma risk GWAS meta-analysis published to 
date (in 2015), including 12,874 cases and 23,203 controls from Australia, USA and Europe2. 
Details of the study population and GWAS quality control measures have been described 
previously2. 
Instrumental variables 
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SNP effect sizes for plasma phospholipid n-3 and n-6 fatty acids levels were derived from a 
study of 8,866 individuals of European ancestry from the cohorts for heart and aging 
research in genomic epidemiology (CHARGE) consortium37, 39. DPA was selected as an 
example to illustrate the MR analysis and interpret the results, with other PUFAs considered 
subsequently (Table 1). The genes FADS1 and FADS2 (desaturates) on chromosome 11, 
ELOVL2 (elongase) on chromosome 6, and GCKR (glucokinase regulator) on chromosome 2 
have been associated with the regulation of DPA metabolism (Supplementary Table 6)37, 40. 
The most significant SNP, rs3734398 in ELOVL2 (allele C), is associated with higher levels of 
EPA, higher levels of DPA (C), and lower levels of DHA. rs174547 (allele C), in the FADS1 gene 
is associated with higher ALA, and lower levels of EPA, and DPA. rs174547(C) is also 
associated with higher levels of LA and lower levels of AA. Furthermore, rs780094 in the 
GCKR gene is associated with higher levels of DPA (allele T)37. However, rs780094 exhibits 
considerable pleiotropy (Supplementary Tables 1-5) and is also associated with melanoma 
(P = 1.3 × 10-2; Supplementary Table 13). As this is likely to violate the assumptions 
underlying MR we have excluded this SNP from the set of instrument variables used. 
These two SNPs (rs3734398, and rs174547) were used as instrumental variables in our 
analysis of DPA. Given the correlations between DPA and the other PUFAs, most of these 
SNPs were commonly used with other PUFAs as instrumental variables - the specific SNPs 
are listed in (Supplementary Tables 6 and 13). All variants selected exceeded the genome-
wide significant threshold (P < 5 × 10-8) for their association with each PUFA, satisfying the 
strong instrument criteria and were not in LD with each other (r2<0.1). 
MR analysis 
R version 3.3.3 was used for the main analysis. Additionally, MR analyses for the 
confounding traits (FBS, BMI, height) were performed using MR-Base 41. 
Statistical Analysis 
Two sample Mendelian randomisation analysis was performed using summary data from 
two different studies. Both studies were comprised of populations of European ancestry. 
The causal inference on melanoma risk by PUFAs was established using Wald-type estimator 
ratio method for individual SNP instruments (Table 1). For each SNP the Wald-type 
estimator divides their effect on the outcome by their exposure effect size; this allows the 
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resultant effect sizes across multiple SNPs to be meta-analysed (IVW method) to obtain a 
single causal effect estimate. (Figure 3) 35.  
Relationship between PUFAs and possible confounding factors 
PUFA levels are associated with other potential confounding factors. We focused on height, 
based on the linking evidence of height associated with melanoma42. If a genetic increase in 
PUFA levels leads to a proportional increase in height but the converse is not true (i.e. genes 
influencing height have no clear effect on PUFA levels) then this is consistent with a causal 
relationship of PUFA levels on height. We drew scatter plots with R version 3.3.3 to visualize 
the correlation in per SNP effect sizes between PUFAs and height. Our aim was to assess if 
changes in height is more likely to be the cause or the consequence of changes in PUFAs (or 
if they are inter-related). Firstly, publicly available genome-wide significant PUFA SNPs were 
selected (P < 5 × 10Ъ8; pruned for linkage disequilibrium r2 < 0.1; DPA 61 SNPs, EPA 39 SNPs, 
ALA 32 SNPs, DHA 6 SNPs, LA 197 SNPs, AA 200 SNPs) and we plotted their PUFA effect sizes 
against height effect sizes. We then performed the reverse using SNPs which were genome-
wide significantly associated with height.  
Results 
Mendelian Randomisation analysis of DPA 
The MR analysis results of the association between DPA concentration and melanoma are 
shown in Table 1. The estimated magnitude of association between DPA level and 
melanoma was performed firstly for each individual SNP using the (Wald type estimator 
ratio method)43. Subsequently a meta-analysis was performed, combining each individual 
Wald type estimator ratio, weighted in inverse proportion to its variance (Figure 3). The 
results are expressed in terms of a さﾉ;ヴｪW Iｴ;ﾐｪWざ ふヰくヱΑ units = one standard deviation in 
DPA). This change was predicted to only negligibly increase melanoma risk (OR = 1.03, 95% 
CI = 0.96に1.10). 
Mendelian Randomisation analysis of non-DPA PUFAs 
The results obtained for the magnitude of association between other PUFAs and risk of 
melanoma is illustrated in Table 2. We obtained similar results for all the PUFAs in our study. 
This is unsurprising as there is overlap between the set of SNPs influencing the measures of 
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different PUFAs. The results indicate no association between any PUFA and melanoma risk. 
Iﾐ W;Iｴ I;ゲW ┘W IﾗﾐゲｷSWヴWS ; さﾉ;ヴｪW Iｴ;ﾐｪWざ ｷﾐ W;Iｴ デヴ;ｷデ (1 SD change): For ALA with a 0.05 
unit change (OR = 0.92, 95% CI = 0.82に1.03), for EPA 0.3 unit change (OR = 0.92, 95% CI = 
0.82に1.04) and DHA for 0.88 unit change (OR = 1.16, 95% CI = 0.90に1.49). The results for n - 
6 fatty acids were: LA with 4 units change (OR = 0.94, 95% CI = 0.86に1.02) and AA with 1.9 
units change (OR = 1.03, 95% CI = 0.99に1.07). 
Checking for violations of MR assumptions  
Validation of instrument strength 
How each poly-unsaturated fatty acid is converted into the next metabolite in the bio 
synthesis pathway is illustrated in figure 244. These fatty acids cannot be synthesized in the 
human body, hence are sourced from the diet. ALA goes through a sequence of reactions 
forming EPA, DPA and DHA. This process is catalyzed by elongases (encoded by the ELOVL2 
gene) and desaturases (encoded by the FADS1 and FADS2 genes). Similarly, conversion of n-
6 fatty acids LA to AA is also regulated by the same enzymes (Figure 2). The SNPs used as 
our genetic instruments are in or near the genes that encode the rate-limiting enzymes for 
fatty-acid conversion. Thus each of the genetic instruments we employ in our study to find 
the association between PUFA and melanoma directly regulates some aspect of the PUFA 
metabolism. This suggests the robust association of the instrumental variables to the 
relevant PUFAs. Furthermore, we selected SNPs for use as instrumental variables from the 
largest PUFA GWAS performed so far, investigating levels of n-3 fatty acids EPA, DPA, DHA 
and ALA (Supplementary Table 6). SNPs used as instrumental variables for n-6 fatty acids 
(AA, LA) were derived from a large scale meta- analysis of GWAS performed from CHARGE 
consortium data39. All SNPs chosen as instrumental variables were associated with the 
relevant PUFA at the level of genome-wide significance (P < 5 × 10-8) - this is more stringent 
than the traditional MR criteria for a strong instrument (F-statistic > 10)38, 45. Furthermore, 
we used multiple genetic variants combined as instrumental variables instead of using 
individual genetic variants to assess causality. This explained more variance than using 
single instrumental variables. As an example, for DPA, if we use rs174547 as a single 
instrumental variable, it would explain 8.3% of the variance in DPA. When we use rs174547 
and rs3734398 together as an instrumental variable, they explain 11.1% of the variance in 
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DPA38. For each PUFA, these combined instruments clearly satisfy the usual criteria for 
strong instruments in MR.  
Population Stratification 
One potential cause of violations of the exclusion restriction assumption and the 
independence assumption is population stratification. In our study both exposure and 
outcome population consist of participants from ethnically homogenous population 
(European ancestry). For the melanoma GWAS meta-analysis, principal components (PCs) 
were used to remove ancestry outliers as well as to model subtle stratification effects by 
including them as covariates in the association analysis. After including these PCs, the 
genomic inflation factor was minimal (1.03)2. Similarly, population substructure control 
using PCs has been performed in the CHARGE consortium data used to identify the 
instrumental variable SNPs for the PUFAs37. 
Pleiotropy assessment 
If the genetic instrument is pleiotropic (has more than one phenotypic effect) and any of the 
secondary phenotypes modify the outcome, this violates the MR assumptions and we 
cannot be certain about the reliability of our findings. These pleiotropic associations may 
either introduce false positive associations or mask the true causal effect estimate of the 
exposure on the outcome. Firstly, potential pleiotropic associations of the various genetic 
instruments were investigated by searching the literature46. 
Then we examined previous GWAS findings to identify associations between the SNPs used 
as instrumental variables and potential biological and socioeconomic confounding factors 
including BMI, height, educational attainment, waist circumference and fasting blood sugar 
(FBS) に (Supplementary Tables 1 to 5). Some SNPs showed associations with height, BMI and 
FBS after Bonferroni correction (Supplementary Tables 1 to 5). We calculated the causal 
effect estimate using the SNPs which are not associated with confounding factors 
(rs3734398 for DPA and rs3798713 for EPA). When this is done our conclusions regarding 
the effect of PUFAs on melanoma are unchanged; For DPA  a 0.17 unit change confers a 
causal OR close to 1 (OR = 0.93, 95% CI = 0.81に1.06). Similarly for EPA for a 0.30 unit change 
(OR = 0.88, 95% CI = 0.67に1.16). Furthermore, the SNPs associated with confounding factors 
do not show any association with melanoma except rs174538 (Supplementary Table 13).   
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We conducted a supplementary analysis, to identify how these putatively confounding 
factors (BMI, height, educational attainment, waist circumference and fasting blood sugar) 
may influence the association of PUFA levels and melanoma. We first looked at height. 
Using an inverse weighted method we found that a 10cm increase in height was associated 
with a small but significant increase in the risk of melanoma (OR= 1.08, 95% CI= 1.01に1.16, 
Supplementary Figure 15). It is hence possible that SNPs which increase height through a 
pathway independent of PUFAs may affect melanoma risk, violating our MR assumptions. 
We investigated whether our selected IV SNPs affect height only via changes in PUFAs by 
generating scatter plots of the SNPs effect sizes to assess the likely causal pathway 
(Methods). For height the SNPs which are associated with DPA had an effect on height (P = 
2.1 × 10-3, r2 = 0.15), EPA (P = 2.9 × 10-2, r2 = 0.13) and LA (P = 1.8 × 10-4, r2 = 0.09) 
(Supplementary Figures 01, 03, 09). Conversely, the reverse was not true where the SNPs 
which are associated with height did not show a strong effect on PUFAs (DPA: P = 0.2, r2 = 
0.003; EPA: P = 0.89, r2 = 2.8× 10-5; LA: P = 0.96, r2 = 3.3× 10-6; Supplementary Figures 02, 04, 
10). These results suggest that height shows vertical pleiotropy, with changes in DPA (and 
EPA, LA) causing changes in height.  Conversely, for ALA a bidirectional association was 
observed; changes to ALA had consequential effects on height (P = 3.8 × 10-3, r2 = 0.25, 
Supplementary Figure 05) and vice versa (P = 2.3 × 10-2, r2 = 0.008, Supplementary Figure 
06). Hence for ALA (but not for DPA, EPA and LA), it is possible that some of our SNP 
instruments affect melanoma risk through a pathway which is independent of the putative 
pathway through ALA. However, the SNPs effect on height is tiny (which are only significant 
due to the very large sample sizes in the height GWAS), and combined with the small effect 
of changes in height on melanoma (OR=1.08 per 10cm increase in height), it is very unlikely 
that this would lead to a violation of the MR assumptions to any substantial extent.  
We then examined whether the SNPs associated with fasting blood sugar (FBS) may violate 
the MR assumptions. We first examined the relationship between FBS and melanoma by 
performing a MR analysis with GWAS significant FBS SNPs on melanoma risk. We found 
there was no causality observed for FBS on melanoma risk (OR = 1.23, 95% CI = 0.77に1.95; 
inverse variance weighted method) (Supplementary Figure 13). It is hence unlikely that the 
effect the SNP IVs have on FBS has any bearing on melanoma risk.  
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We then considered BMI. As for FBS, we found that BMI was not causally related to 
melanoma risk (OR= 1.03, 95% CI = 0.88に1.21) (Supplementary figure 14). It is hence unlikely 
that the effect the SNP IVs have on BMI is relevant to melanoma risk. Finally, although we 
cannot be certain regarding unmeasured confounders, it is unlikely that the genetic variants 




There has been much work done on the potentially causal role of modifiable risk factors on 
cancer. Diet is particularly attractive, as proven causal links would motivate the adoption of 
relatively easily integrated life style changes. Observational epidemiological studies 
conducted to date have not provided clear guidance on the role of PUFAs in melanoma risk. 
Hence, we explored the causal association of PUFA levels with melanoma risk using a 
Mendelian randomisation approach. If we take DPA as an example, our results identified 
that a very large (0.17 unit change - 1 SD) increase in DPA levels had little or no effect on the 
risk of melanoma (OR = 1.03, 95% CI = 0.96 に1.10). Hence, it is unlikely that DPA (or any 
other PUFAs) play an important role in determining the risk of melanoma. Usually null 
association results are considered stronger than positive results in MR because while a 
positive result can be driven by an unmeasured confounder, this is less likely to occur with a 
negative finding. To get a negative result solely due to confounding effects would require a 
similar magnitude of both (true) positive and negative confounding effects (which cancel the 
effect estimates on each other out exactly), which is very unlikely 47.  
Our result is  inconsistent with the observation of Fortes et al., in which consumption of fish 
containing high n-3 was found to be protective for melanoma (OR = 0.52, 95% CI = 0.34に
0.78)25. There are several possible reasons the results from the two studies are inconsistent. 
Unlike MR studies, these observational study findings are susceptible to confounding effects 
(or incomplete correction for confounding), such as socio-economic status and sun 
exposure. Furthermore, the hospital-based case control study data in the study by Fortes et 
al. were collected retrospectively using questionnaires. It is likely that information biases 
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such as recall bias and imperfect measures on food portion size adversely affected their 
results. 
The complex metabolic pathways of these PUFAs, their inter-relations, and the influence of 
different SNPs are well understood (Figure 2). In MR analysis validity of the causal inference 
is determined by satisfying the prior mentioned assumptions. Our chosen genetic variants 
have well-established specific roles in the PUFA biological pathway, making them highly 
suitable instruments for MR analysis. The main strength of our study was the very large 
sample size used for analyses. We derived the causal effect estimates of SNPs and the 
outcomes from the largest melanoma risk GWAS to date2. Similarly, we had causal effect 
estimates for the SNP-risk factor association from the largest PUFA GWAS to date, 
conducted using 8,826 individuals. We used two different samples to generate the summary 
data for our analyses. Using a two sample MR approach has an advantage over one sample 
MR, because effect estimates are more accurately measured than from a single study 
because of the larger sample sizes which leads to increase the statistical power48. One of the 
limitations in the MR approach is that it requires a large sample size because most genetic 
instruments explain very little of the variation in the exposure of interest. However, the 
instrument used here explained relatively large amounts of the variance in some of the 
PUFA levels (AA = 33.1%, LA = 8.3-21.3%). Moreover, we used independent SNPs combined 
together as instrumental variables, rather than a single variant, which further increased the 
variance explained and thus the statistical power to discern the true relationship between 
exposure and outcome.  
One of the limitations of our study is that we cannot rule out the possible effect of other, 
unmeasured confounders. Although we tested the SNP instruments to check for potential 
pleiotropic effects for BMI, height, level of education, waist circumference and fasting 
glucose level, there may be potentially confounding effects from other variables, such as UV 
exposure, number of atypical moles and phenotypes (hair, eye and skin colour), for which 
we did not have data. Presence of directional pleiotropy can be identified using MR-Egger 
regression and drawing a funnel plot43 although in our case we did not have enough SNP 
instruments for such approaches to be informative. Most genetic instruments explained a 
high proportion of the variance for the trait, for some PUFAs a smaller fraction of variance 
(ALA = 1.0%, DHA = 0.7%, EPA = 2.1%) was explained, reducing our power to detect small 
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effects of these PUFAs on melanoma risk in our MR framework. Furthermore, identifying the 
effects of individual PUFAs on melanoma risk was difficult due to shared instrumental 
variables among the PUFAs. 
Conclusion 
We used multiple SNP genetic instruments to examine the effect of raising PUFA levels 
(percentage of total fatty acids). Even large changes in genetically determined PUFA levels 
were not found to be associated with melanoma risk. Whilst some observational studies 
have suggested that the Mediterranean diet reduces the risk of melanoma, our results from 
analysing one constituent of this diet に PUFAs - suggest that the effect of increased PUFA 
levels on melanoma risk are either zero or very small. We used an analytically robust MR 
approach, which negates the issues of residual confounding and reverse causality, two 
issues that adversely affect the interpretation of results from observational studies.  
Thus, we therefore conclude that any protective role of the Mediterranean diet on 
melanoma risk is not due to PUFAs. Further studies are needed to explore the causality of 
other components of the Mediterranean diet for possible effects on melanoma risk. 
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Tables 
Table 1: Mendelian randomisation results: DPA concentration and melanoma 
SNP Gene CHR EA/NEA R2 é DPA ゝ DPA é melanoma ゝ melanoma EAF é IVW ゝ IVW 
rs174547 FADS1 11 T/C 8.4% 0.075 0.0028 0.027 0.018 0.67 0.36 0.24 
rs3734398 ELOVL2 6 C/T 2.8% 0.040 0.0029 -0.017 0.017 0.43 -0.42 0.43 
Combined    11.2%        0.17 0.21 
 
EA - Effect allele, NEA - Non-effect allele, R2 に Percentage of variance of DPA explained by the SNP(s), é DPA - Magnitude of the association of 
SNP(s) and modifiable exposure (DPA). ゝ DPA - Standard error of the magnitude of association between SNP(s) and DPA, é melanoma - 
Magnitude of the association between SNP(s) and outcome (melanoma), ゝ ﾏWﾉ;ﾐﾗﾏ; - Standard error of the magnitude of the association 
between SNP(s) and melanoma, EAF - Effect allele frequency, é IVW - in log (OR) scale , magnitude of association between DPA and melanoma 
(for a 1unit of DPA change), ゝ IVW - Standard error of the magnitude of association between DPA and melanoma. Note: é DPA estimates were 
directly taken from Lemaitre et al., 37 and é melanoma estimates were taken from Law et al., 2 The percentage variance of DPA explained were 
obtained from Khankari et al., 38
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Table 2: Mendelian randomisation results: PUFA and melanoma 
 
Trait Scale OR 95%CI 
LA 4 0.94 0.86に1.02 
AA 1.9 1.03 0.99に1.07 
ALA 0.05 0.92 0.82に1.03 
EPA 0.30 0.92 0.82に1.04 
DPA 0.17 1.03 0.96に1.10 
DHA 0.88 1.16 0.90に1.49 
    
    
Scale - Units of PUFA change which is equal to 1SD deviation in CHARGE cohort, DPA - 
Docosapentaenoic acid, DHA - Docosahexaenoic acid, EPA - Eicosapentaenoic acid, ALA - ü - 
linolenic acid, AA - Arachidonic acid, LA - Linoleic acid 




Figure 1: Directed Acyclic Graph (DAG) depiction of our study of PUFA and risk of 
melanoma 




Figure 2: PUFA metabolic pathway, annotated with loci associated with PUFA metabolism: 
n-6 rounded rectangle (left), n-3 grey rounded rectangle (right) 





Figure 3: Equation - Inverse variance weighted method35 
 - Estimated magnitude of effect of the modifiable exposure (PUFA) on outcome 
(melanoma) 
 - Standard deviation of the effect of the modifiable exposure on outcome  
 
- Estimated magnitude of the effect of the instrumental variables (SNP(s)) on the 
modifiable exposure  
 
- Estimated magnitude of the effect of the instrumental variables on outcome  
ゝ
zy 
- Standard deviation of the effect of the instrumental variables on outcome 
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